News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,877 Results
Type
Article (42020)
Company Profile (267)
Press Release (687574)
Multimedia
Podcasts (114)
Webinars (20)
Section
Business (205165)
Career Advice (2053)
Deals (35683)
Drug Delivery (131)
Drug Development (81796)
Employer Resources (174)
FDA (16552)
Job Trends (15036)
News (347522)
Policy (32924)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2603)
Accelerated approval (46)
Adcomms (28)
Allergies (168)
Alliances (49665)
ALS (200)
Alzheimer's disease (1767)
Antibody-drug conjugate (ADC) (433)
Approvals (16901)
Artificial intelligence (636)
Autoimmune disease (256)
Automation (52)
Bankruptcy (363)
Best Places to Work (11659)
BIOSECURE Act (21)
Biosimilars (217)
Biotechnology (176)
Bladder cancer (187)
Brain cancer (69)
Breast cancer (721)
Cancer (5655)
Cardiovascular disease (461)
Career advice (1739)
Career pathing (41)
CAR-T (317)
CDC (58)
Celiac Disease (2)
Cell therapy (847)
Cervical cancer (45)
Clinical research (70691)
Collaboration (2011)
Company closure (5)
Compensation (1330)
Complete response letters (78)
COVID-19 (2850)
CRISPR (104)
C-suite (1070)
Cystic fibrosis (150)
Data (7504)
Decentralized trials (3)
Denatured (27)
Depression (157)
Dermatology (73)
Diabetes (572)
Diagnostics (6894)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (307)
Drug pricing (208)
Drug shortages (31)
Duchenne muscular dystrophy (277)
Earnings (91397)
Editorial (66)
Employer branding (22)
Employer resources (153)
Events (119042)
Executive appointments (1062)
FDA (20157)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (34)
Funding (1677)
Gene editing (226)
Generative AI (54)
Gene therapy (692)
GLP-1 (1056)
Government (4793)
Grass and pollen (6)
Guidances (403)
Healthcare (18999)
HIV (77)
Huntington's disease (53)
IgA nephropathy (93)
Immunology and inflammation (282)
Immuno-oncology (86)
Indications (173)
Infectious disease (3189)
Inflammatory bowel disease (208)
Inflation Reduction Act (14)
Influenza (137)
Intellectual property (282)
Interviews (321)
IPO (16665)
IRA (53)
Job creations (3685)
Job search strategy (1447)
JPM (62)
Kidney cancer (18)
Labor market (96)
Layoffs (565)
Leadership (38)
Legal (8011)
Liver cancer (99)
Longevity (32)
Lung cancer (753)
Lymphoma (421)
Machine learning (58)
Management (59)
Manufacturing (990)
MASH (181)
Medical device (13896)
Medtech (13989)
Mergers & acquisitions (20227)
Metabolic disorders (1485)
mRNA (206)
Multiple sclerosis (182)
NASH (17)
Neurodegenerative disease (398)
Neuropsychiatric disorders (101)
Neuroscience (3228)
Neurotech (1)
NextGen: Class of 2026 (6536)
Non-profit (4532)
Now hiring (76)
Obesity (702)
Opinion (292)
Ovarian cancer (207)
Pain (244)
Pancreatic cancer (287)
Parkinson's disease (352)
Partnered (33)
Patents (582)
Patient recruitment (636)
Peanut (61)
People (59597)
Pharmaceutical (59)
Pharmacy benefit managers (34)
Phase 1 (22029)
Phase 2 (31127)
Phase 3 (23211)
Pipeline (7840)
Policy (324)
Postmarket research (2573)
Preclinical (9371)
Press Release (64)
Prostate cancer (289)
Psychedelics (55)
Radiopharmaceuticals (317)
Rare diseases (1034)
Real estate (5980)
Recruiting (71)
Regulatory (25321)
Reports (55)
Research institute (2416)
Resumes & cover letters (357)
Rett syndrome (36)
RNA editing (20)
RSV (94)
Schizophrenia (174)
Series A (281)
Series B (207)
Service/supplier (11)
Sickle cell disease (110)
Special edition (25)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3655)
State (2)
Stomach cancer (18)
Supply chain (128)
Tariffs (94)
The Weekly (85)
Vaccines (1144)
Venture capital (104)
Weight loss (458)
Women's health (120)
Worklife (20)
Date
Today (171)
Last 7 days (714)
Last 30 days (2805)
Last 365 days (30268)
2026 (10373)
2025 (30251)
2024 (35290)
2023 (40142)
2022 (51239)
2021 (55813)
2020 (54165)
2019 (46584)
2018 (35073)
2017 (32215)
2016 (31594)
2015 (37611)
2014 (31378)
2013 (26373)
2012 (28610)
2011 (29299)
2010 (27357)
Location
Africa (748)
Alabama (91)
Alaska (7)
Arizona (341)
Arkansas (14)
Asia (39709)
Australia (6496)
California (12773)
Canada (3651)
China (1302)
Colorado (546)
Connecticut (553)
Delaware (391)
Europe (85833)
Florida (1912)
Georgia (410)
Hawaii (3)
Idaho (62)
Illinois (1020)
India (88)
Indiana (582)
Iowa (23)
Japan (514)
Kansas (129)
Kentucky (50)
Louisiana (39)
Maine (75)
Maryland (1532)
Massachusetts (9094)
Michigan (353)
Minnesota (696)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (138)
New Hampshire (84)
New Jersey (3382)
New Mexico (28)
New York (3356)
North Carolina (1616)
North Dakota (8)
Northern California (6368)
Ohio (378)
Oklahoma (23)
Oregon (41)
Pennsylvania (2574)
Puerto Rico (28)
Rhode Island (50)
South America (1118)
South Carolina (85)
South Dakota (2)
Southern California (5026)
Tennessee (206)
Texas (2015)
United States (45125)
Utah (380)
Vermont (1)
Virginia (305)
Washington D.C. (80)
Washington State (1026)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
729,877 Results for "pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Patents
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the U.S. last year.
April 29, 2026
·
2 min read
·
Nick Paul Taylor
Breast cancer
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 billion in sales.
March 17, 2026
·
1 min read
·
Annalee Armstrong
Pipeline
Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer
Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.
April 24, 2026
·
2 min read
·
Tristan Manalac
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin treatment.
March 2, 2026
·
2 min read
·
Tristan Manalac
Earnings
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
February 3, 2026
·
4 min read
·
Annalee Armstrong
Vaccines
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trial—but failed to hit a predetermined confidence interval.
March 23, 2026
·
2 min read
·
Heather McKenzie
Obesity
Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’
With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, “Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets said Tuesday.
February 3, 2026
·
2 min read
·
Tristan Manalac
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.
April 2, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed execs for more details; Merck and Roche also released Q4 and full year earnings, with Eli Lilly, Novo Nordisk and others reporting Wednesday; REGENXBIO hits a regulatory snag ahead of its upcoming PDUFA; more.
February 4, 2026
·
1 min read
·
Heather McKenzie
Gene editing
Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy
Pfizer will be responsible for all global clinical and regulatory activities for Beam Therapeutics’ liver-directed gene editor.
February 26, 2026
·
1 min read
·
Tristan Manalac
1 of 72,988
Next